CD19 and systemic lupus erythematosus: A case series with follow-up of eight SLE patients has raised cautious optimism for anti-CD19 CAR-T cell therapy in SLE, particularly regarding deep B-cell depletion, disease remission, seroconversion, cytokine modulation, refractory immune thrombocytopenia, reactivity profiles, GMP-grade preparation, and safety (9, 10, 99–104).